The science is clear. The treatment is already here — leucovorin is used daily in Norwegian hospitals. We are respectfully asking Norwegian health authorities to recognise this pathway for children with autism and FRAA positivity, so that families who need it are not left without options.
Folate receptor alpha autoantibodies (FRAA) block the transport of folate across the blood-brain barrier, reducing cerebral folate availability — a condition known as Cerebral Folate Deficiency (CFD). In children, CFD is associated with a range of neurodevelopmental symptoms. The condition is measurable through a specific antibody test, and it is treatable: high-dose folinic acid (leucovorin) can bypass the blocked receptor and restore folate delivery to the brain.
FRAA positivity is not a rare finding. A systematic review and meta-analysis of 21 studies (Rossignol & Frye, Journal of Personalised Medicine, 2021) found FRAA in approximately 71% of children with autism spectrum disorder — compared to low single-digit percentages in neurotypical controls. A Belgian study documented FRAA positivity in 47% of children with ASD versus 3.3% in a developmental control group. Research from Phoenix Children's Hospital and the MIND Institute (University of California) across four placebo-controlled trials demonstrated measurable effects of leucovorin on core autism-related symptoms in FRAA-positive children. In March 2026, the U.S. Food and Drug Administration (FDA) approved leucovorin specifically for Cerebral Folate Deficiency — the first formal regulatory recognition of this treatment pathway in a major jurisdiction. The American Academy of Pediatrics (AAP) has published clinical guidance for paediatricians on its use.
In Norway, FRAA testing is available — but expensive and not reimbursed. Most families cannot access it without covering the full cost themselves. More critically: even those who do test positive have no pathway to treatment. Leucovorin is not available for this indication in Norway. A positive FRAA result currently has no clinical consequence. A diagnosis without a treatment pathway is not a clinical tool — it is a dead end.
And yet leucovorin is not a new or foreign drug in Norway. It is used every day in Norwegian oncology wards as part of standard colorectal cancer protocols — including the Nordic FLOX regimen developed in Scandinavia, as well as FOLFOX and FOLFIRI. The drug is here. The Norwegian healthcare system already uses it. What is missing is recognition of this additional indication.
Formally recognise leucovorin (folinic acid) — already approved and in daily use in Norway for oncological indications — for the additional indication of Cerebral Folate Deficiency in FRAA-positive children with neurodevelopmental diagnoses.
Develop clinical guidelines on FRAA testing as part of the diagnostic pathway for children with ASD and ADHD diagnoses — and establish recommended dosing protocols for leucovorin where FRAA positivity is confirmed and a clinician deems treatment indicated.
Evaluate reimbursement of FRAA testing and leucovorin for this indication — following formal recognition by Statens legemiddelverk — so that access is not determined by a family's financial means.
Autistic children in Norway deserve the same access to an evidence-based diagnostic and treatment pathway as children in countries where this pathway already exists. When a clinician identifies a biological finding and an internationally recognised intervention exists, the healthcare system should make it possible to act on that finding. Every signature on this statement represents a family, a clinician, or an individual who believes this gap needs to close.
This statement will be submitted to all three authorities, with a request for formal meetings to discuss the evidence and the steps needed to complete this clinical pathway.
This statement is prepared by Nordic Nutrition and Metabolic Center for Child Development (NNMCCD), org.nr 937 889 151 — a registered non-profit organisation in Norway. It represents the collective position of the organisation and its member community.
Your name will be included in our formal submission to Statens legemiddelverk, Helsedirektoratet, and Beslutningsforum — as evidence of community need and support for this clinical pathway.
A statement adds weight. A membership builds the structure. Every member gives NNMCCD the institutional credibility needed to be heard — in grant applications, research partnerships, and conversations with health authorities.
Membership 200 NOK / year. Every member gives NNMCCD the institutional weight needed to be heard by health authorities and grant bodies.